Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE: ABT) reported fourth-quarter 2025 and full-year results and issued 2026 guidance. 4Q25 GAAP diluted EPS $1.01; adjusted diluted EPS $1.50 (+12%). Full-year 2025 GAAP diluted EPS $3.72; adjusted diluted EPS $5.15 (+10%). Full-year 2025 sales were $44.3 billion (+5.7% reported; +5.5% organic). Abbott projects 2026 organic sales +6.5% to +7.5% and adjusted diluted EPS $5.55–$5.80 (midpoint ≈ +10%). Company expects Exact Sciences acquisition to close in Q2 2026 and noted FDA approval for the Volt PFA System and CE Mark for TactiFlex Duo.
Abbott (NYSE: ABT) received CE Mark on Jan 20, 2026 for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled, enabling commercial use in the European Union for treating atrial fibrillation (AFib).
TactiFlex Duo delivers dual-energy therapy (radiofrequency and pulsed field ablation) and completed its first commercial EU cases this week. CE Mark was supported by the FOCALFLEX CE Mark study showing clinically meaningful safety and effectiveness. The catheter integrates with Abbott's EnSite™ X mapping system. Abbott previously secured Volt PFA System approvals in 2025 and obtained FDA Breakthrough Device designation for VT in Oct 2025.
Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, 2026, before the market opens.
The results will be followed by a live webcast of the earnings conference call at 8:00 a.m. Central / 9:00 a.m. Eastern, accessible via Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later the same day.
Abbott (NYSE: ABT) launched Libre Assist on Jan. 5, 2026 — a free feature in the Libre app that uses generative AI and FreeStyle Libre continuous glucose monitoring (CGM) data to guide in-the-moment food decisions for people living with diabetes.
Users can snap a photo or enter text to get a color-coded glucose-impact prediction (green/yellow/orange), actionable meal tips to lower impact, and post-meal confirmation using personal Libre CGM sensor data. Libre Assist is available at no extra cost in the Libre app on Apple App Store and Google Play.
Abbott (NYSE: ABT) announced FDA approval of its Volt™ Pulsed Field Ablation (PFA) System to treat atrial fibrillation on Dec 22, 2025. Approval was based on the VOLT-AF IDE study of 392 patients across 40 centers in the U.S., Europe, Canada and Australia, showing clinically meaningful safety and effectiveness for both paroxysmal and persistent AFib. Volt is an all-in-one PFA catheter with a proprietary balloon-in-basket design, integration with Abbott’s EnSite X mapping system, fewer therapy applications, reduced fluoroscopy, and the option for procedures under conscious sedation. Abbott will begin U.S. commercial cases and continue EU site expansion.
Abbott (NYSE: ABT) announced FDA clearance and CE Mark for the Amplatzer Piccolo Delivery System to be used with the Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA) in premature infants.
The delivery system is designed for the tiniest babies (some as small as ~2 pounds), enables single-catheter procedures, and aims to improve placement precision and reduce adverse events. The Amplatzer Piccolo Occluder was previously approved in 2019. The announcement highlights Abbott's pediatric structural heart portfolio and provides links for important safety information.
Abbott (NYSE: ABT) announced a 6.8% increase in its quarterly common dividend to $0.63 per share. The dividend is payable Feb. 13, 2026 to shareholders of record at the close of business on Jan. 15, 2026.
This raises the company's quarterly payout more than 70% since 2020, marks Abbott's 54th consecutive year of dividend growth and is the 408th consecutive quarterly dividend paid since 1924. Abbott remains a member of the S&P 500 Dividend Aristocrats.
Abbott (NYSE: ABT) announced Lingo, its over-the-counter continuous glucose monitor and app, is now available on Android, expanding access beyond iOS in the U.S. and U.K.
Lingo is intended for adults 18+ not using insulin and offers real-time glucose data and a daily metric, Lingo Count, to quantify glucose spikes. Abbott reported that reducing Lingo Count over about three months halves time above the healthy range and lowers average glucose by 10%. Real-world data showed protein supplementation days had 15% lower odds of glucose spikes and a 2 mg/dL average glucose reduction ( 18% odds and 3 mg/dL reduction among people with obesity).
Abbott (NYSE: ABT) and the Big Ten reported that the second annual "We Give Blood" drive (Aug. 27–Dec. 5, 2025) produced 83,043 donations, a 319% increase versus 2024, and could help save up to 250,000 lives. The University of Wisconsin led with 15,476 donations and will receive a $1 million Abbott award to advance student or community health. Student donors rose 168%, with 92% of participants saying they are likely to donate again. The campaign aimed to address a national blood shortage and boost younger donor participation.
Abbott (NYSE: ABT) on Dec. 4, 2025 launched two Ensure Max Protein shakes aimed at muscle health: Ensure Max Protein 42g for active adults (42 g protein, 23 vitamins/minerals, 2 electrolytes, 2 g sugar, 220 calories) and Ensure Max Protein 2 in 1 Muscle Support for older adults (30 g protein, 1.5 g CaHMB, 26 vitamins/minerals). Abbott cited muscle loss after age 40 and described HMB research spanning 25+ years. Real-world data from >9,500 users of Abbott's Lingo continuous glucose monitor found 15% lower odds of elevated glucose on days users consumed protein shakes. The products are exclusive at Walmart through March 2026, with wider retail distribution beginning April 2026.
FAQ
What is the current stock price of Abbott Labs (ABT)?
What is the market cap of Abbott Labs (ABT)?
